SLNO Key Statistics, Chart & Performance
The current stock price of SLNO is 50.01 USD. In the past month the price increased by 7.99%. In the past year, price increased by 7.06%.
SLNO Latest News, Press Relases and Analysis
SLNO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.6 | 394.11B | ||
| AMGN | AMGEN INC | 14.35 | 169.00B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 148.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 110.88B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.39 | 72.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 814.14 | 54.85B | ||
| INSM | INSMED INC | N/A | 41.41B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.5 | 25.80B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.05 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B | ||
| INCY | INCYTE CORP | 14.82 | 18.68B |
Related stock screener links
About SLNO
Company Profile
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 133 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Company Info
SOLENO THERAPEUTICS INC
100 Marine Parkway, Suite 400
Redwood City CALIFORNIA 94065 US
CEO: Anish Bhatnagar
Employees: 92
Phone: 16502138444
SOLENO THERAPEUTICS INC / SLNO FAQ
What does SOLENO THERAPEUTICS INC do?
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 133 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
What is the current price of SLNO stock?
The current stock price of SLNO is 50.01 USD. The price decreased by -2.29% in the last trading session.
Does SOLENO THERAPEUTICS INC pay dividends?
SLNO does not pay a dividend.
How is the ChartMill rating for SOLENO THERAPEUTICS INC?
SLNO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of SOLENO THERAPEUTICS INC (SLNO) based on its PE ratio?
SOLENO THERAPEUTICS INC (SLNO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).
What is the ownership structure of SOLENO THERAPEUTICS INC (SLNO)?
You can find the ownership structure of SOLENO THERAPEUTICS INC (SLNO) on the Ownership tab.
SLNO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SLNO. When comparing the yearly performance of all stocks, SLNO turns out to be only a medium performer in the overall market: it outperformed 46.06% of all stocks.
SLNO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLNO. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability.
SLNO Financial Highlights
Over the last trailing twelve months SLNO reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 44.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.08% | ||
| ROE | -15.85% | ||
| Debt/Equity | 0.1 |
SLNO Forecast & Estimates
19 analysts have analysed SLNO and the average price target is 115.81 USD. This implies a price increase of 131.57% is expected in the next year compared to the current price of 50.01.